News Center
In 2019, the list of the top 100 pharmaceutical companies in China was released, and Chairman Zhu Baoguo participated in the roundtable forum.
Release time:
2020-09-02
The 37th National Pharmaceutical Industry Information Annual Conference was grandly opened yesterday in Zhuhai. The conference released the list of the top 100 Chinese pharmaceutical companies for 2019, the list of the best industrial enterprises in China's pharmaceutical R&D product lines for 2020, and awarded the Excellent Project Award for Social Responsibility of Chinese Pharmaceutical Enterprises for 2020.
The original text is missing, so no translation can be provided.
Lijun Group ranked 30th on the list of the top 100 Chinese pharmaceutical companies for 2019, ranked 12th on the list of the best industrial enterprises in China's pharmaceutical R&D product lines for 2020, and won the Excellent Project Award for Social Responsibility for 2020.
As a representative of the top 100 enterprises, Lijun Group Chairman Zhu Baoguo participated in the roundtable forum with many well-known domestic entrepreneurs.At the forum, Chairman Zhu Baoguo shared Lijun's specific practices and experiences in the field of R&D innovation. He pointed out that pharmaceutical R&D must first have innovative thinking, secondly be able to endure loneliness, and at the same time pursue R&D progress. Lijun's approach is to continuously increase R&D investment, respect the achievements of scientists and researchers, and enhance employee happiness.
Lijun was awarded the Excellent Project Award for Social Responsibility of the Year for its outstanding contributions to society in areas such as earthquake relief and targeted poverty alleviation over the years. This is also a high recognition of Lijun Group's continuous practice of social responsibility.
Since the beginning of this year, various industries have been impacted by the pandemic. Lijun has delivered a good performance report thanks to its excellent performance in advantageous areas such as the digestive field, raw material drug field, and diagnostic reagents, benefiting from Lijun's rich product pipeline.
Looking to the future, Lijun will continue to strengthen its internal capabilities, integrate advantageous resources, accelerate R&D progress, provide more high-quality and efficient products for a wide range of patients, and make greater contributions to the Chinese national pharmaceutical industry.
Related Information